Compare VNO & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNO | TWST |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.2B |
| IPO Year | 1994 | 2018 |
| Metric | VNO | TWST |
|---|---|---|
| Price | $37.75 | $116.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $33.00 | ★ $46.88 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ 10400.00 | 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,810,425,000.00 | $376,572,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | $5.42 | $15.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.27 | ★ 20.32 |
| 52 Week Low | $24.57 | $23.30 |
| 52 Week High | $43.37 | $126.40 |
| Indicator | VNO | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 58.20 |
| Support Level | $36.31 | $84.39 |
| Resistance Level | $41.28 | N/A |
| Average True Range (ATR) | 1.12 | 8.24 |
| MACD | -0.29 | 0.99 |
| Stochastic Oscillator | 5.71 | 77.53 |
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.